XML 63 R17.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Goodwill and Other Intangible Assets, Net | 6 Months Ended
--- | ---
Oct. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Other Intangible Assets, Net | Goodwill and Other Intangible Assets, Net The changes in the carrying amount of goodwill for the six months ended October 30, 2015 are as follows:
(in millions) | Cardiac and Vascular Group |  | Minimally Invasive Therapies Group |  | Restorative Therapies Group |  | Diabetes Group |  | Total
Balance as of April 24, 2015 | $ | 5,855 |  |  | $ | 23,399 |  |  | $ | 9,424 |  |  | $ | 1,852 |  |  | $ | 40,530 |
Goodwill as a result of acquisitions | 409 |  |  | 132 |  |  | 191 |  |  | — |  |  | 732 |
Purchase accounting adjustments, net | 24 |  |  | (9 | ) |  | 5 |  |  | — |  |  | 20 |
Currency adjustment, net | (6 | ) |  | — |  |  | (3 | ) |  | 1 |  |  | (8 | )
Balance as of October 30, 2015 | $ | 6,282 |  |  | $ | 23,522 |  |  | $ | 9,617 |  |  | $ | 1,853 |  |  | $ | 41,274 |
During the six months ended October 30, 2015, the Company recorded $20 million of purchase accounting adjustments, net, primarily related to the Covidien acquisition. See Note 3 to the condensed consolidated financial statements for additional information on purchase accounting adjustments related to the Covidien acquisition. The gross carrying amount and accumulated amortization of intangible assets at October 30, 2015 and April 24, 2015 are as follows:
| October 30, 2015 |  | April 24, 2015
(in millions) | Gross Carrying Amount |  | Accumulated Amortization |  | Gross Carrying Amount |  | Accumulated Amortization
Amortizable: |  |  |  |  |  |  |
Customer-related | $ | 18,579 |  |  | $ | (801 | ) |  | $ | 18,492 |  |  | $ | (273 | )
Purchased technology and patents | 11,265 |  |  | (2,560 | ) |  | 11,118 |  |  | (2,268 | )
Trademarks and tradenames | 850 |  |  | (408 | ) |  | 640 |  |  | (363 | )
Other | 84 |  |  | (47 | ) |  | 79 |  |  | (44 | )
Total | $ | 30,778 |  |  | $ | (3,816 | ) |  | $ | 30,329 |  |  | $ | (2,948 | )
Non-Amortizable: |  |  |  |  |  |  |
IPR&D | $ | 769 |  |  |  |  | $ | 470 |  |  |
Tradenames | — |  |  |  |  | 250 |  |  |
Total | $ | 769 |  |  |  |  | $ | 720 |  |  |
Amortization expense for the three and six months ended October 30, 2015 was $483 million and $964 million, respectively, and for the three and six months ended October 24, 2014 was $89 million and $176 million, respectively. Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets as of October 30, 2015, excluding any possible future amortization associated with acquired IPR&D, which has not met technological feasibility, is as follows:
(in millions) Fiscal Year | Estimated Amortization Expense
Remaining 2016 | $ | 964 |
2017 | 1,913 |
2018 | 1,882 |
2019 | 1,789 |
2020 | 1,741 |
2021 | 1,724 |
The Company assesses the impairment of goodwill annually in the third quarter at the reporting unit level and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The aggregate carrying amount of goodwill was $41.274 billion and $40.530 billion as of October 30, 2015 and April 24, 2015, respectively. The Company did not record any goodwill impairment during the three and six months ended October 30, 2015 or October 24, 2014. The Company assesses IPR&D for impairment annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The aggregate carrying amount of IPR&D was $769 million and $470 million as of October 30, 2015 and April 24, 2015, respectively. Similar to the goodwill impairment test, the IPR&D impairment test requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of IPR&D asset fair values over their carrying values utilizing a discounted future cash flow analysis. During the three and six months ended October 30, 2015 and October 24, 2014, the Company did not record any significant IPR&D impairments. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances or other failures to achieve a commercially viable product, and as a result, may record impairment losses in the future. The Company assesses intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset (asset group) may not be recoverable. The aggregate carrying amount of intangible assets, excluding IPR&D and non-amortizable tradenames, was $26.962 billion and $27.381 billion as of October 30, 2015 and April 24, 2015, respectively. When events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recorded based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did not record any significant intangible asset impairments during the three and six months ended October 30, 2015 or October 24, 2014.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration